EP
BEAM icon

Edgestream Partners’s Beam Therapeutics BEAM Stock Holding History

Edgestream Partners’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.32M Buy
+96,651
New +$2.92M 0.1% 380
2025
Q4 		– Sell
-41,664
Closed -$1.01M – 948
2025
Q3 		$1.01M Buy
+41,664
New +$829K 0.03% 628

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Edgestream Partners's BEAM Position: Q2 2026 in Review

Edgestream Partners opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 96,651 shares worth $3.32M. The stake represents 0.1% of the portfolio and ranks #380 among its holdings. This is a return to the name: Edgestream Partners previously reported a position in BEAM as recently as Q3 2025.

Edgestream Partners first reported a position in BEAM in Q3 2025 and has held it in 2 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Edgestream Partners held 96,651 shares of Beam Therapeutics worth $3.32M as of Q2 2026.
  • Beam Therapeutics was a new Edgestream Partners position in Q2 2026.
  • Beam Therapeutics made up 0.1% of Edgestream Partners's portfolio in Q2 2026, its #380 holding.
  • Edgestream Partners first reported a position in Beam Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.